On March 9, the world witnessed a milestone in the fight against COVID: The first human case of the coronavirus was confirmed in the United States, and the virus has since spread throughout the world.

This has been the most rapid and deadly coronaviral pandemic since 1918, with more than 6,000 deaths, and a global toll of more than 3.6 billion people.

The pandemic is a challenge for Canada, but not just because of the risk to its citizens.

As we know from the Ebola crisis, there is a lot at stake for the health-care system in Canada as well.

In the years ahead, we will be faced with the challenge of finding ways to protect the health and safety of Canadians.

This is a challenging time for our country.

It’s a time of great uncertainty, and it’s a difficult time to be a Canadian.

It means that our healthcare system has to adapt.

To that end, we’re looking to introduce a new kind of vaccine.

That’s why we’re developing a new type of vaccine for COVID.

We want to take a different approach than we’ve used for past COVID vaccines, and that’s the concept of a vaccine that targets the immune system.

The idea is to develop a vaccine for the body that targets specific molecules, rather than specific cells.

In other words, we want to use molecules that are already part of our immune system to target a specific antigen.

The key word is “target.”

The concept behind this vaccine is that it targets specific antibodies to the virus, which is the mainstay of COVID infection.

In essence, we believe that we’re trying to use an immunotherapeutic agent to treat the COVID virus, rather that it’s targeting specific cells within the body.

For those of you who are curious, the main antibodies that are found in our body are those of the body’s own immune system, called T cells.

And these T cells are normally produced in the brain and are responsible for recognizing foreign molecules in the environment, such as foreign viruses and bacteria.

For a vaccine to work, it has to be able to effectively kill specific cells in the body, which means targeting the immune cells.

For example, if you take a piece of paper and stick it into the bloodstream, the T cells in your blood can pick up that paper and send it to the brain, which will then activate the immune response.

In this case, the vaccine is targeting a molecule called a COV-1 antibody, which we know is expressed in the immune cell surface proteins that line the surface of the immune membrane.

This molecule binds to COV, which then activates the T cell immune response, and this immune response is able to kill a specific COV antibody in the bloodstream.

The goal is to make the vaccine work in a way that will work well in people, and to be effective against the disease.

What’s different about this vaccine?

The key thing is that the vaccine does not have a central manufacturing facility.

The vaccine is produced in small factories around the world, in Canada.

This means that the manufacturing process can be as low-tech as possible, and has the advantage that it allows for rapid and high quality testing.

That means the vaccine will be tested in the field at least as soon as it’s produced, which gives the vaccine more time to reach the market.

There is also the additional advantage that we are not limited by the requirements of the countries where we have to produce the vaccine, because the vaccines we are developing are not going to be manufactured in countries where there are strong regulatory systems in place.

It also means that we don’t have to wait until the pandemic has passed to apply the vaccine to our population.

This will allow us to do things like vaccinate people in areas that are not exposed to the pandemics, which would help our economy during the crisis.

The other advantage of having a vaccine developed in Canada is that we can make the vaccines more readily available in Canada, so that Canadians can get them sooner.

This gives us a chance to make vaccines that work for more people, so we can be able more quickly to get the vaccine out to people who are more susceptible to the disease, so they can be protected.

There are many challenges ahead.

The world is still recovering from the previous pandemic, and we know that there will be a lot of challenges ahead of us.

We have a long way to go, and our government and the people of Canada need to continue to lead the way in developing and implementing a comprehensive response to the crisis in the coming years.

We know that Canadians are very passionate about this disease, and so we’re going to continue working to do everything we can to make sure that Canadians receive the best possible care.

Thank you, Dr. Marc Nadler, for joining us on the panel.

Dr. Nadler is a